Eli Lilly & Co. (LLY) & Incyte (INCY) Report Positive Top-Line Results from the North American Phase 3 Study (BREEZE-AD5) of Oral Selective JAK Inhibitor Baricitinib

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/12/2026

1. ORCL
2. SPY
3. SPCX
4. USO
5. CHWY
6. NAVN
7. CRWV
8. CME
9. ADBE
10. HUMA

Go back to Eli Lilly & Co. (LLY) & Incyte (INCY) Report Positive Top-Line Results from the North American Phase 3 Study (BREEZE-AD5) of Oral Selective JAK Inhibitor Baricitinib
Incyte Genomics, Inc. (NASDAQ: INCY) Delayed: 107.83 +2.44 (2.32%)
Previous Close $105.39    52 Week High $118.49 
Open $105.97    52 Week Low $55.00 
Day High $109.69    P/E N/A 
Day Low $104.08    EPS $-0.56 
Volume 2,318,314       

Lilly (Eli) & Co. (NYSE: LLY) Delayed: 1160.95 +24.58 (2.16%)
Previous Close $1136.37    52 Week High $88.16 
Open $1139.71    52 Week Low $67.88 
Day High $1170.12    P/E 268.74 
Day Low $1125.64    EPS $4.32 
Volume 2,764,755